REPLIGEN CORP APIC, Share-based Payment Arrangement, Increase for Cost Recognition
REPLIGEN CORP (RGEN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-29
- REPLIGEN CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.01M, a 4.32% decline year-over-year.
- REPLIGEN CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.32M, a 14.42% increase year-over-year.
- REPLIGEN CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $7.98M, a 25.55% increase year-over-year.
- REPLIGEN CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.97M, a 61.08% decline year-over-year.
- REPLIGEN CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $32.60M, a 32.17% decline from fiscal 2024.
- REPLIGEN CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $48.07M, a 87.96% increase from fiscal 2023.
- REPLIGEN CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $25.57M, a 6.37% decline from fiscal 2022.
- REPLIGEN CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $27.32M, a 0.67% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.01M 10-Q · filed 2026-07-29 | $16.34M 10-Q · filed 2026-07-29 | $24.32M derived: sum of 3 quarters · filed 2026-07-29 | $33.29M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2026-03-31 | $8.32M 10-Q · filed 2026-05-06 | $16.31M derived: sum of 2 quarters · filed 2026-05-06 | $25.28M derived: sum of 3 quarters · filed 2026-05-06 | $33.65M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2025-12-31 | $7.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.96M derived: sum of 2 quarters · filed 2026-02-26 | $25.33M derived: sum of 3 quarters · filed 2026-07-29 | $32.60M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $8.97M 10-Q · filed 2025-11-04 | $17.35M derived: sum of 2 quarters · filed 2026-07-29 | $24.62M 10-Q · filed 2025-11-04 | $30.98M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2025-06-30 | $8.38M 10-Q · filed 2026-07-29 | $15.65M 10-Q · filed 2026-07-29 | $22.01M derived: sum of 3 quarters · filed 2026-07-29 | $45.06M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2025-03-31 | $7.27M 10-Q · filed 2026-05-06 | $13.63M derived: sum of 2 quarters · filed 2026-05-06 | $36.69M derived: sum of 3 quarters · filed 2026-05-06 | $46.57M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $29.41M derived: sum of 2 quarters · filed 2026-02-26 | $39.29M derived: sum of 3 quarters · filed 2026-02-26 | $48.07M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $23.05M 10-Q · filed 2025-11-04 | $32.93M derived: sum of 2 quarters · filed 2025-11-04 | $41.71M 10-Q · filed 2025-11-04 | $48.17M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $9.88M 10-Q · filed 2025-08-07 | $9.21M 10-Q · filed 2024-07-30 | $18.66M 10-Q · filed 2025-08-07 | $17.99M 10-Q · filed 2024-07-30 | $25.12M derived: sum of 3 quarters · filed 2026-02-26 | $31.49M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $8.78M 10-Q · filed 2025-04-29 | $15.24M derived: sum of 2 quarters · filed 2026-02-26 | $21.61M derived: sum of 3 quarters · filed 2026-02-26 | $27.10M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $6.46M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $12.84M derived: sum of 2 quarters · filed 2026-02-26 | $18.32M derived: sum of 3 quarters · filed 2026-02-26 | $25.57M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $6.37M 10-Q/A · filed 2024-11-18 | $11.86M derived: sum of 2 quarters · filed 2024-11-18 | $19.11M 10-Q/A · filed 2024-11-18 | $25.37M derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-06-30 | $5.48M 10-Q/A · filed 2024-11-18 | $12.74M 10-Q/A · filed 2024-11-18 | $19.00M derived: sum of 3 quarters · filed 2025-03-14 | $25.15M derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2023-03-31 | $7.25M 10-Q/A · filed 2024-11-18 | $13.52M derived: sum of 2 quarters · filed 2025-03-14 | $19.67M derived: sum of 3 quarters · filed 2025-03-14 | $26.66M derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2022-12-31 | $6.26M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $12.42M derived: sum of 2 quarters · filed 2025-03-14 | $19.40M derived: sum of 3 quarters · filed 2025-03-14 | $27.32M 10-K · filed 2025-03-14 | |||
| 2022-09-30 | $6.15M 10-Q/A · filed 2024-11-18 | $13.14M derived: sum of 2 quarters · filed 2024-11-18 | $21.05M 10-Q/A · filed 2024-11-18 | $28.08M derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2022-06-30 | $6.99M 10-Q/A · filed 2024-11-18 | $14.90M 10-Q/A · filed 2024-11-18 | $21.92M derived: sum of 3 quarters · filed 2024-11-18 | $28.72M derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2022-03-31 | $7.92M 10-Q/A · filed 2024-11-18 | $14.94M derived: sum of 2 quarters · filed 2024-11-18 | $21.73M derived: sum of 3 quarters · filed 2024-11-18 | $28.87M derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2021-12-31 | $7.02M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $13.82M derived: sum of 2 quarters · filed 2024-11-18 | $20.96M derived: sum of 3 quarters · filed 2024-11-18 | $27.50M 10-K/A · filed 2024-11-18 | |||
| 2021-09-30 | $6.79M 10-Q · filed 2022-11-01 | $13.94M derived: sum of 2 quarters · filed 2022-11-01 | $20.48M 10-Q · filed 2022-11-01 | $24.99M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2021-06-30 | $7.14M 10-Q · filed 2022-08-02 | $13.68M 10-Q · filed 2022-08-02 | $18.20M derived: sum of 3 quarters · filed 2023-02-22 | $22.42M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2021-03-31 | $6.54M 10-Q · filed 2022-04-27 | $11.06M derived: sum of 2 quarters · filed 2023-02-22 | $15.28M derived: sum of 3 quarters · filed 2023-02-22 | $19.38M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2020-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $8.74M derived: sum of 2 quarters · filed 2023-02-22 | $12.84M derived: sum of 3 quarters · filed 2023-02-22 | $17.01M 10-K · filed 2023-02-22 | |||
| 2020-09-30 | $4.22M 10-Q · filed 2021-10-28 | $8.33M derived: sum of 2 quarters · filed 2021-10-28 | $12.49M 10-Q · filed 2021-10-28 | $15.88M derived: sum of 4 quarters · filed 2022-02-17 | |||
| 2020-06-30 | $4.10M 10-Q · filed 2021-07-27 | $8.27M 10-Q · filed 2021-07-27 | $11.65M derived: sum of 3 quarters · filed 2022-02-17 | $14.83M derived: sum of 4 quarters · filed 2022-02-17 | |||
| 2020-03-31 | $4.17M 10-Q · filed 2021-05-04 | $7.55M derived: sum of 2 quarters · filed 2022-02-17 | $10.73M derived: sum of 3 quarters · filed 2022-02-17 | $13.76M derived: sum of 4 quarters · filed 2022-02-17 | |||
| 2019-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $6.56M derived: sum of 2 quarters · filed 2022-02-17 | $9.59M derived: sum of 3 quarters · filed 2022-02-17 | $12.85M 10-K · filed 2022-02-17 | |||
| 2019-09-30 | $3.17M 10-Q · filed 2020-11-05 | $6.21M derived: sum of 2 quarters · filed 2020-11-05 | $9.46M 10-Q · filed 2020-11-05 | $11.98M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-06-30 | $3.03M 10-Q · filed 2020-07-30 | $6.28M 10-Q · filed 2020-07-30 | $8.80M derived: sum of 3 quarters · filed 2021-02-24 | $11.58M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-03-31 | $3.25M 10-Q · filed 2020-05-06 | $5.77M derived: sum of 2 quarters · filed 2021-02-24 | $8.55M derived: sum of 3 quarters · filed 2021-02-24 | $11.18M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2018-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $5.30M derived: sum of 2 quarters · filed 2021-02-24 | $7.92M derived: sum of 3 quarters · filed 2021-02-24 | $10.19M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $2.78M 10-Q · filed 2019-10-31 | $5.40M derived: sum of 2 quarters · filed 2019-10-31 | $7.67M 10-Q · filed 2019-10-31 | ||||
| 2018-06-30 | $2.63M 10-Q · filed 2019-08-01 | $4.89M 10-Q · filed 2019-08-01 | |||||
| 2018-03-31 | $2.27M 10-Q · filed 2019-05-09 | ||||||
| 2017-12-31 | $6.75M 10-K · filed 2020-02-26 | ||||||
| 2016-12-31 | $4.59M 10-K · filed 2019-03-01 | ||||||
| 2015-12-31 | $3.60M 10-K · filed 2018-02-22 | ||||||
| 2014-12-31 | $1.77M 10-K · filed 2017-02-23 | $1.77M 10-K · filed 2015-03-17 | |||||
| 2013-12-31 | $1.06M 10-K · filed 2016-02-25 | $1.06M 10-K · filed 2014-03-14 | |||||
| 2012-12-31 | $1.02M 10-K · filed 2015-03-17 | ||||||
| 2011-12-31 | $730.14K 10-K · filed 2013-03-15 | $730.14K 10-K · filed 2014-03-14 | |||||
| 2011-03-31 | $1.00M 10-K · filed 2013-03-15 | ||||||
| 2010-03-31 | $1.01M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |